報價延遲最少15分鐘:2025/07/16 15:04 EDT
常規時段
|
|
|
|
|
||||||||||||
|
|
|
|
|
2.01 
|
|
|
| 價值評估 |
|
盈利(現時/預測)
-0.26/-0.55
|
|
企業價值
85.55M
|
| 資產負債 |
|
每股賬面淨值
0.43
|
| 現金流量 |
|
現金流量率
--
|
| 損益表 |
|
收益
181.00K
|
|
每股收益
0.00
|
|
同行比較
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
報價延遲最少15分鐘：2025/07/16 15:04 EDT
同行比較之報價最少15分鐘延遲
|
業務概覽
|
|||
| Entera Bio Ltd is a clinical-stage biopharmaceutical company engaged in the development of orally delivered macromolecule therapeutics, including peptides and therapeutic proteins. The company focuses on underserved, chronic medical conditions where oral administration of a mini tablet peptide or peptide replacement therapy has the potential to significantly shift a treatment paradigm. Its product candidates are; EB613 for the treatment of osteoporosis and EB612 for the treatment of hypoparathyroidism are first-in-class mini tablet formulations of synthetic human PTH (1-34) (teriparatide), designed to have differing pharmacokinetic, or PK, profiles. |
